Comparing two diabetes drugs' effect on early retinal changes
Treatments studied
Part of Eyes & vision, Heart & circulation, Hormones & metabolism clinical trials.
This study looks at how starting a GLP-1 receptor agonist (like Trulicity) or an SGLT2 inhibitor (like Jardiance) affects blood sugar and small blood vessels in the eyes of people with type 2 diabetes. If you have mild or no diabetic eye disease, you may be able to help researchers learn which medication might be better for your eyes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have type 2 diabetes.
- Your doctor has decided, on their own, to start you on a GLP-1 receptor agonist or an SGLT2 inhibitor for the first time.
- Your eye exam shows either no diabetic eye damage or only a mild form of it.
- Your HbA1c is 7.0% or higher within 30 days of your eye check.
- You can have clear eye scans and follow-up visits.
- You have not taken either study drug before and do not have other serious eye conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is looking at whether newer diabetes drugs (like SGLT2 inhibitors and DPP-4 inhibitors) can help protect the eyes of people with long-standing type 2 diabetes. The study focuses on preventing or slowing diabetic retinopathy, a common eye complication.
This study measures blood flow in the eyes and how the retina (back of the eye) uses oxygen in people with diabetes who are starting a new type of diabetes medication. Researchers want to understand how these newer medications affect blood vessels in the eyes.
This study looks at early damage to the retina (the back of the eye) in people with type 2 diabetes, even before vision problems start. It aims to find new ways to detect and treat diabetic eye disease early.
This study compares two different two-drug combinations for people recently diagnosed with type 2 diabetes. It aims to find which combination works better to control blood sugar and improve overall health.
This study follows people with type 2 diabetes to understand how diabetic retinopathy (an eye disease caused by diabetes) changes over time without treatment. It may help if you have no other eye issues causing new blood vessels and are not planning for certain eye procedures.
This study tests if starting two newer diabetes drugs (empagliflozin and semaglutide) soon after diagnosis, along with metformin, helps control blood sugar better than metformin alone. It's for people diagnosed with type 2 diabetes in the last two years who are already taking a high dose of metformin.
Hear when a new Type 2 Diabetes Mellitus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.